Immune protein patterns precede prostate cancer diagnoses by years
Blood collected well before diagnosis linked several immune proteins with later prostate cancer in a peer-reviewed observational and genetic study. Associations emerged when European cohort results were combined with UK Biobank data; none passed statistical correction in the European cohort alone. Some genetic findings ran in the opposite direction, complicating the proposed role of immune surveillance. No preventive treatment or screening test was evaluated.
Science··Night
Blood samples precede the disease
A single peer-reviewed investigation connected blood protein measurements with later prostate cancer diagnoses using prospective cohorts and genetic analyses. A long-term European cohort supplied 1,434 cases and matched controls. Researchers measured 368 proteins involved in immunity and inflammation. None passed the correction for multiple comparisons for overall cancer in that cohort alone. Combining results with UK Biobank, a health-research database, yielded several associations.[1]
Some associations persist across a long interval
Higher concentrations of some proteins linked to immune surveillance were associated with a lower occurrence of prostate cancer. Immune surveillance refers to the recognition of abnormal cells by the body’s defences. Several relationships appeared in blood drawn more than 7 years before diagnosis. That timing makes changes immediately preceding diagnosis a less likely explanation, while leaving other influences unresolved. Associations for more aggressive disease were less conclusive, limiting extrapolation from the overall cancer findings.[1]
Genetic estimates complicate the protective interpretation
Genetic variants associated with protein levels offered another way to examine the relationship. For some proteins, these estimates pointed in the opposite direction to the prospective blood measurements. Different biological processes and time scales could contribute to the disagreement. The work investigated pathways involving the immune system without testing an intervention. It established neither the preventive effect of raising a protein nor the clinical usefulness of a screening test; functional experiments and independent validation remain necessary.[1]
